Caribou Biosciences Announces Closing of Upsized Initial Public Offering
July 27 2021 - 4:05PM
Business Wire
Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading
clinical-stage CRISPR genome-editing biopharmaceutical company,
announced today the closing of its previously announced initial
public offering of 19,000,000 shares of common stock, at a price to
the public of $16.00 per share. In addition, Caribou has granted
the underwriters a 30-day option to purchase up to an additional
2,850,000 shares of common stock at the initial public offering
price, less the underwriting discounts and commissions.
The aggregate gross proceeds to Caribou from the offering were
approximately $304.0 million, before deducting underwriting
discounts and commissions and other offering expenses payable by
Caribou. The shares began trading on the Nasdaq Global Select
Market on July 23, 2021, under the ticker symbol “CRBU.”
BofA Securities, Citigroup, and SVB Leerink acted as joint
book-running managers for this offering.
Registration statements relating to the offering were filed with
the U.S. Securities and Exchange Commission (the “SEC”) and became
effective on July 22, 2021. Copies of the registration statements
can be accessed through the SEC’s website at www.sec.gov. The
offering was made only by means of a prospectus forming part of the
effective registration statements. Copies of the final prospectus
relating to this offering may be obtained from: BofA Securities,
NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC
28255-0001, Attention: Prospectus Department, or by email at
dg.prospectus_requests@bofa.com; Citigroup, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
by telephone at (800) 831-9146 or by email at prospectus@citi.com;
or SVB Leerink LLC, Attention: Syndicate Department, 53 State
Street, 40th Floor, Boston, MA 02109, or by telephone at (800)
808-7525, ext. 6105, or by email at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing
biopharmaceutical company dedicated to transforming the lives of
patients with devastating diseases by applying the company’s
proprietary chRDNA technology toward the development of
next-generation, genome-edited allogeneic immune cell therapies.
The company is developing a pipeline of genome-edited,
off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of
both hematologic malignancies and solid tumors. The therapies
target cell surface antigens for which autologous CAR-T cell
therapeutics have previously demonstrated clinical proof-of-concept
as well as additional emerging targets.
For more information about Caribou, visit www.cariboubio.com and
follow the company @CaribouBio.
“Caribou Biosciences” and the Caribou logo are registered
trademarks of Caribou Biosciences, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210727006010/en/
Caribou Biosciences, Inc. Media Contact: Greg
Kelley Ogilvy gregory.kelley@ogilvy.com 617-461-4023
Caribou Biosciences, Inc. Investor Relations
Contact: Elizabeth Wolffe, Ph.D. and Sylvia Wheeler Wheelhouse
LSA lwolffe@wheelhouselsa.com swheeler@wheelhouselsa.com
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024